

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

We claim:

Claim 1. (Previously Presented) A process for the preparation of a highly concentrated, liquid formulation comprising monoclonal antibody c225 (Mab c225) or monoclonal antibody h425 (Mab h425), comprising ultrafiltrating a preparation comprising said Mab c225 or Mab h425, wherein the concentration of said antibody in said highly concentrated, liquid formulation thus prepared is 50 mg/ml to 180 mg/ml.

Claim 2. (Cancelled)

Claim 3. (Cancelled)

Claim 4. (Previously Presented) The process according to Claim 1, wherein the concentration of said antibody in said highly concentrated, liquid formulation is 100 – 150 mg/ml.

Claim 5. (Cancelled)

Claim 6. (Cancelled)

Claim 7. (Cancelled)

Claim 8. (Previously Presented) A highly concentrated, liquid formulation comprising monoclonal antibody c225 (Mab c225) or monoclonal antibody h425 (Mab h425), wherein the concentration of said antibody in said highly concentrated, liquid formulation thus prepared is 50 mg/ml to 180 mg/ml.

Claim 9. (Cancelled)

Claim 10. (Cancelled)

Claim 11. (Previously Presented) The highly concentrated, liquid formulation according to Claim 8, wherein the concentration of said antibody is 100 – 150 mg/ml.

Claim 12. (Cancelled)

Claim 13. (Cancelled)

Claim 14. (Cancelled)

Claim 15. (Cancelled)

Claim 16. (Currently Amended) A storage-stable pharmaceutical preparation which comprises a highly concentrated, liquid formulation according to claim [[7]] 1 and an acceptable excipient or adjuvant.

Claim 17. (Currently Amended) A highly concentrated, liquid formulation according to Claim 8 which optionally further comprises an excipient, adjuvant or an additional pharmaceutical active ingredient which is an antioxidant, a buffer, a bacteriostatic or a solute.

Claim 18. (Withdrawn) Use of a highly concentrated, liquid formulation according to Claim 8 for the preparation of a medicament.

Claim 19. (Withdrawn) A method for the treatment and/or prophylaxis of a tumor or tumor metastasis, comprising administering to a subject in need thereof, the highly concentrated, liquid formulation according to claim 8.

Claim 20. (Withdrawn) The method according to Claim 19, wherein the tumor is brain tumor, tumor of the urogenital tract, tumor of the lymphatic system, stomach tumor, laryngeal tumor, monocytic leukemia, lung adenocarcinoma, small-cell lung carcinoma, pancreatic cancer, glioblastoma or breast carcinoma.

Claim 21. (Currently Amended) A kit which comprises a highly concentrated, liquid formulation according to claim [[7]] 1 and an additional medicament active ingredient which is an antioxidant, a buffer, a bacteriostatic or a solute.

Claim 22. (Previously Presented) A process for the preparation of a highly concentrated, liquid formulation comprising monoclonal antibody c225 (Mab c225) or monoclonal antibody h425 (Mab h425) consisting essentially of ultrafiltrating a preparation comprising said Mab c225 or Mab h425, wherein the concentration of said antibody in said highly concentrated, liquid formulation thus prepared is 50 mg/ml to 180 mg/ml.

Claim 23. (Previously Presented) A highly concentrated, liquid formulation consisting

essentially of monoclonal antibody c225 (Mab c225) or monoclonal antibody h425 (Mab h425), wherein the concentration of said antibody in said highly concentrated, liquid formulation is 50 mg/ml to 180 mg/ml.

Claim 24. (Previously Presented) The highly concentrated, liquid formulation according to Claim 23, wherein the concentration of said antibody is 100 – 150 mg/ml.